<DOC>
	<DOC>NCT02847598</DOC>
	<brief_summary>The primary objective of the study is to evaluate the efficacy of BIIB059 in reducing skin disease activity in participants with systemic lupus erythematosus (SLE) (Part A), and in participants with active cutaneous lupus erythematosus (CLE) with or without systemic manifestations (Part B), and to investigate the dose response relationship in participants with active SLE and skin manifestations (Part A only). Secondary objective is to evaluate additional efficacy parameters of BIIB059 in reducing SLE disease activity.</brief_summary>
	<brief_title>Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<mesh_term>Lupus Erythematosus, Cutaneous</mesh_term>
	<criteria>Key 1. All women of childbearing potential and all men must practice effective contraception during the study and for 4 months after their last dose of study treatment. 2. CLASIA â‰¥ 8 at Screening and Randomization. Key 1. Active lupus nephritis or moderatetosevere or chronic kidney disease. 2. Any active skin conditions other than CLE that may interfere with the study (e.g., psoriasis, nonLE skin lupus, druginduced lupus). 3. History of chronic, recurrent, or recent serious infection. 4. Active clinically significant viral, bacterial, or fungal infection, or any major episode of infection requiring hospitalization or treatment with parenteral antiinfectives within 4 weeks of or during Screening, or completion of oral antiinfectives within 2 weeks before or during Screening. 5. Use of immunosuppressive or diseasemodifying treatments for SLE that were initiated less than 3 months prior to Screening. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CLE, SLE, Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus, Lupus</keyword>
</DOC>